Novo Preempts Earnings Reveal With Preview Of Wegovy-Driven Growth

Blockbuster Obesity Treatment To Face New Rival This Year

Novo Nordisk said sales increased 25% in the first quarter, driven by US demand for GLP-1 agonist Wegovy for obesity, and increased its 2023 sales growth guidance from a range of 13%-19% to 24%-30%.

Syringe with a needle and yellow measuring tape. Injections for body beauty and weight loss.
Novo projects significant growth from its weight loss leader Wegovy • Source: Shutterstock

Excitement about the sales potential of GLP-1 agonists for the treatment of obesity is so strong that Novo Nordisk A/S is boasting about the performance of its top-seller in the class, Wegovy (semaglutide), nearly three weeks ahead of its first quarter earnings report scheduled for 4 May. The Danish big pharma announced on 13 April that its total product sales increased 25% in Q1 versus the same period in 2022, largely due to increased US demand for Wegovy, and it now is projecting 24%-30% companywide sales growth for the year, up from prior guidance of 13%-19%.

Novo also said operating profit growth was 28% in the first quarter and the company now expects operating profit growth...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

Test

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.